Medicinal products for human use

Responses to the Public consultation on draft revision 3 of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use

Publication of responses to the Public consultation on draft revision 3 of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial.

Below are the public responses to the abovementioned consultation paper. The following submitting parties requested their submission not to be published: Actogenix.

Additional information: